Sumatriptan/naproxen sodium for migraine: Efficacy, health related quality of life, and satisfaction outcomes

Headache

Volumn 47, Issue 5, 2007, Pages 683-692

  Smith, Timothy ^a   Blumenthal, Harvey ^b   Diamond, Merle ^c   Mauskop, Alexander ^d   Ames, Michael ^e   McDonald, Susan ^e   Lener, Shelley ^e   Burch, Steven ^e  

^a Mercy Health Research and Ryan Headache Center   (United States)

^b Neurological Associates of Tulsa   (United States)

^c Diamond Headache Clinic   (United States)

^d New York Headache Center   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Migraine; Quality of life; Satisfaction

Indexed keywords

NAPROXEN PLUS SUMATRIPTAN;

ADULT; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DYSPEPSIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MULTICENTER STUDY; MUSCLE TIGHTNESS; NAUSEA; OPEN STUDY; PARESTHESIA; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SOMNOLENCE; TABLET FORMULATION; THORAX PAIN; THROAT TIGHTNESS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; SUMATRIPTAN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 34248370471     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2007.00790.x     Document Type: Article

References (33)

1. Lipton RB, Stewart WF, Von KM. Burden of migraine: Societal costs and therapeutic opportunities. Neurology. 1997 48 (3 Suppl 3 S4 S9.
2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001 41 : 646 657.
3. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med. 1999 159 : 813 818.
4. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992 2 : 67 76.
5. Stang PE, Crown WH, Bizier R, Chatterton ML, White R. The family impact and costs of migraine. Am J Manag Care. 2004 10 : 313 320.
6. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. Headache. 1994 34 : 337 343.
7. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ. The impact of migraine on quality of life in the general population: The GEM study. Neurology. 2000 55 : 624 629.
8. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: A population-based case-control study from England. Cephalalgia. 2003 23 : 441 450.
9. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: The global Migraine and Zolmitriptan Evaluation survey. Headache. 2003 43 : 19 26.
10. Magnusson JE, Becker WJ. Migraine frequency and intensity: Relationship with disability and psychological factors. Headache. 2003 43 : 1049 1059.
11. Data on File. GlaxoSmithKline Sumatriptan Periodic Safety Update Report, 01 April 2005 to 30 September 2005. Document number GM/2005/00431/00.
12. Pilgrim AJ. Long-term tolerability, safety, and efficacy of sumatriptan. Cephalalgia. 1993 13 : 190. Abstract.
13. Tansey MJB, Pilgrim AJ, Martin PM. Long-term experience with sumatriptan in the treatment of migraine. Eur Neurol. 1993 33 : 310 315.
14. Rederich G, Rapoport A, Cutler N, Hazelrigg R, Jamerson B. Oral sumatriptan for the long-term treatment of migraine: Clinical findings. Neurology. 1995 45 (Suppl 7 S15 S20.
15. Barbanti P, Carpay JA, Kwong WJ, Ahmad F, Boswell D. Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine. Curr Med Res Opin. 2004 20 : 2749 2758.
16. Savani N, Pfaffenrath V, Rice L, Black L, Jones M for the Sumatriptan SUMB4007 Study Group. Efficacy, tolerability, and patient satisfaction with 50- and 100-mg sumatriptan tablets in those initially dissatisfied with efficacy of 50-mg sumatriptan tablets. Clin Ther. 2001 23 : 260 271.
17. Cady RC, Ryan R, Jhingran P, O'Quinn S, Pait G. Sumatriptan injection reduces productivity loss during a migraine attack: Results of a double-blind. Arch Intern Med. 1998 158 : 1013 1018.
18. Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005 45 : 983 991.
19. Brandes JL, O'Carroll PC, Mannix LK, Lener SE, Littlefield D, Alexander WJ. Therapeutic clinical benefits of a single-tablet formulation of sumatriptan formulated with RT Technology™ and naproxen sodium. Cephalalgia. 2005 25 : 860. Abstract.
20. Cady R, Rothrock J, Blumenthal H, Ward T, Ames M, Burch S. Treatment satisfaction with a new single-tablet formulation of sumatriptan formulated with RT Technology™ and naproxen sodium. Neurology. 2006 66 (suppl 2 A42.
21. Landy S, Smith T, Diamond M, Rapoport A, Ames M, Burch S. Impact of a new single-tablet formulation of sumatriptan formulated with RT Technology™ and naproxen sodium on workplace productivity and activity time. Neurology. 2006 66 (Suppl 2 A43.
22. Winner P, Cady RK, Ruoff GE, et al Twelve-month tolerability and safety of sumatriptan/naproxen sodium for the actue treatment of migraine. Headache. 2006 46 : 859. Abstract.
23. Davis KH, Black L, Sleath B. Validation of the Patient Perception of Migraine Questionnaire. Value Health. 2002 5 : 421 429.
24. Martin BC, Pathak DS, Sharfman MI, et al Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache. 2000 40 : 204 215.
25. Data on file. GSK psychometric analysis of the migraine specific quality of life questionnaire [Version 2.0]: Using combined data from RESA 2016 and RESA 2017. Document number RM1998/00389/00.
26. Patrick DL, Martin ML, Bushmell DM, Pesa J. Measuring satisfaction with migraine treatment: Expectations, importance, outcomes, and global ratings. Clin Ther. 2003 25 : 2920 2935.
27. Luciani RJ, Osterhaus JT, Gutterman DL. Patient preferences for migraine therapy: Subcutaneous sumatriptan compared with other medications. J Fam Pract. 1995 41 : 147 152.
28. Pilgrim AJ. Long-term tolerability, safety, and efficacy of sumatriptan. Cephalalgia. 1993 13 : 190. Abstract.
29. Tansey MJ, Pilgrim AJ, Martin PM. Long-term experience with sumatriptan in the treatment of migraine. Eur Neurol. 1993 33 : 310 315.
30. Rederich G, Rapoport A, Cutler N, Hazelrigg R, Jamerson B. Oral sumatriptan for the long-term treatment of migraine: Clinical findings. Neurology. 1995 45 (8 Suppl 7 S15 S20.
31. Silberstein SD, Stark S, DeRossett SE, Taylor D, McDonald SA, Lener S. Superior clinical benefits of a new single-tablet formulation of sumatriptan formulated with RT technology and naproxen sodium. Neurology. 2006 66 (suppl 2 A254 A255.
32. Brandes JL, Kudrow D, Stark S, et al Superior efficacy of combination therapy over monotherapy: Results of a fixed single-tablet formulation of Sumatriptan RT technology and naproxen sodium in the acute treatment of migraine in the traditional treatment paradigm. Headache. 2006 46 : 860.
33. Ferrari MD, Roon KL, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet. 2001 358 : 1668 1675.